Head-to-Tail Cyclization of α-Conotoxin TxID Leads to Enhanced Stability in Serum
Author:
BİÇEN KARAKOÇ Nurcan1ORCID, AKCAN Muharrem1ORCID
Affiliation:
1. KÜTAHYA DUMLUPINAR ÜNİVERSİTESİ
Abstract
Peptide biomolecules have important bioactivities and hence their use in drug design and development studies has increased in recent years. Conotoxins are natural peptides that obtained from cone snail venoms and have the potential to be used for chronic pain treatment, Parkinson's disease, schizophrenia, obesity and cancer due to their effects on the nervous system. However, their use as medicines has been limited as they can be easily broken down by many proteolytic enzymes in the body. Several modification methods are used to overcome these disadvantages. Cyclization of the peptide backbone is one such method and has been used to stabilize various linear peptides. In this study, the N- and C-termini of α-conotoxin TxID with two disulfide bridges were joined using a six amino acid long GGAAGG linker peptide chain to cyclize the peptide backbone and the serum stability of the cyclized peptide was examined. The cyclic TxID peptide remained intact about 50% in human serum after 24 hours.
Publisher
Gazi University Journal of Science
Subject
Multidisciplinary,General Engineering
Reference44 articles.
1. [1] Craik, D.J., Fairlie, D.P., Liras, S., and Price, D., “The Future of Peptide-based Drugs”, Chemical Biology & Drug Design, 81(1): 136–147, (2013). 2. [2] Reiss, S., Sieber, M., Oberle, V., Wentzel, A., Spangenberg, P., Claus, R., Kolmar, H., Lösche, W., “Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins ” ,Platelets, 17(3): 153–157, (2006). 3. [3] Kadin, H., “Captopril.” In: Florey KBT-AP of DS, editor. Academic Press, 79–137, (1982). 4. [4] Terlau, H., and Olivera, B.M., “Conus venoms: a rich source of novel ion channel-targeted peptides”, Physiological Reviews, 84(1): 41–68, (2004). 5. [5] Shen, G.S., Layer, R.T., and McCabe, R.T., “Conopeptides: From deadly venoms to novel therapeutics”, Drug Discovery Today, 5(3): 98–106, (2000).
|
|